^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiKa (camrelizumab)

    i
    Other names: INCSHR1210, SHR-1210, HR-301210, INCSHR-1210, SHR1210, HR301210, HR 301210, INCSHR 1210, SHR 1210
    Company:
    CG Invites, Elevar Therapeutics, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    ESCC-PT: Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2/3 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Gilotrif (afatinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • AiRuiKang (dalpiciclib)
    6d
    A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=48, Completed, Sun Yat-sen University | Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    6d
    Characteristics and hematological indicators predictors of immunotherapy response in advanced non-small cell lung cancer. (PubMed, BMC Cancer)
    Baseline hematological markers (NLR, PLR, ALBI, LDH) are valuable predictors of efficacy and prognosis in advanced NSCLC patients undergoing immunotherapy. Their prognostic roles vary by pathological subtype: squamous carcinoma relies more on inflammatory markers, while adenocarcinoma emphasizes metabolic markers and genetic mutations. This study provides a hematological biomarker-based stratification framework for individualized immunotherapy decisions in advanced NSCLC, offering critical guidance for optimizing treatment and prognosis management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab)
    6d
    A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, Harbin Medical University
    New trial • Real-world evidence
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Zepsun (donafenib)
    7d
    PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma (clinicaltrials.gov)
    P1/2, N=112, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P1/2 trial
    |
    AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
    8d
    The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=715, Completed, Tongji Hospital
    New trial
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Stivarga (regorafenib) • Zepsun (donafenib)
    9d
    Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Sheng Tai
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811)
    14d
    Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Hunan Cancer Hospital
    New P2 trial
    |
    cisplatin • carboplatin • paclitaxel • AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    15d
    Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=164, Recruiting, The First Affiliated Hospital of Henan University of Science and Technology
    New P2 trial
    |
    carboplatin • AiRuiKa (camrelizumab) • capecitabine • albumin-bound paclitaxel
    17d
    A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors (clinicaltrials.gov)
    P=N/A, N=208, Not yet recruiting, Henan Cancer Hospital
    New trial
    |
    AFP (Alpha-fetoprotein)
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    20d
    Metachronous hepatocellular carcinoma after partial response of advanced intrahepatic cholangiocarcinoma treated with radiotherapy combined with apatinib and camrelizumab: a case report. (PubMed, Front Oncol)
    Radiotherapy combined with anti-angiogenic and immunotherapy is an effective option for advanced unresectable iCCA. It also emphasizes that active pathological biopsy is essential for new hepatic lesions after iCCA remission to clarify diagnosis and avoid misdiagnosis-induced inappropriate treatment.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    20d
    Tumor flare-like response: A novel imaging phenomenon with predictive significance in triple negative breast cancer patients undergoing neoadjuvant immuno-chemotherapy. (PubMed, Breast)
    TFLR is a frequent, reversible MRI finding in TNBC treated with camrelizumab-based neoadjuvant immuno-chemotherapy. Largest nodule diameter ≥9 mm is a strong, independent predictor of pathological complete response and represents a promising early, non-invasive imaging biomarker of immunotherapeutic efficacy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab)